Reaction

Neurological Decompensation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,243 reports · 100 co-occurring drugs

As of the last recalculation, Neurological Decompensation appears in 2,243 FAERS reports alongside 100 co-occurring drug terms. The strongest observed disproportionality signal is ALTEPLASE (PRR 132.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alteplase	196	132.6	134.4
Ganciclovir	31	28.5	28.6
Bleomycin Sulfate	31	28.2	28.3
Ganciclovir Sodium	31	27.5	27.6
Fondaparinux Sodium	20	23.1	23.2
Amphotericin B	27	20.2	20.3
Thiotepa	19	18.6	18.6
Voriconazole Injection	40	17.4	17.4
Valganciclovir Hydrochloride Powder,	19	14.6	14.6
Daptomycin	14	14.2	14.2
Voriconazole	44	13.7	13.7
Ado-Trastuzumab Emtansine	12	13.3	13.3
Carboxymethylcellulose Sodium	13	12.9	12.9
Fludarabine Phosphate	53	12.8	12.8
Axicabtagene Ciloleucel	13	12.3	12.3
Temozolomide	27	12.0	12.0
Valganciclovir	24	11.9	11.9
Valganciclovir Hydrochloride	24	11.9	11.9
Melphalan Hydrochloride	31	11.6	11.6
Melphalan	28	11.6	11.6
Pegaspargase	15	11.4	11.5
Sevoflurane	10	11.2	11.2
Etoposide	84	11.0	11.0
Cytarabine	69	11.0	11.0
Propofol	42	10.9	10.9
Levetiracetam In Sodium Chloride	87	10.8	10.8
Levetiracetam Oral	87	10.8	10.8
Levetiracetam Injection	87	10.8	10.8
Busulfan	17	10.1	10.1
Dexamethasone Sodium Phosphate	11	10.1	10.1
Insulin Glargine-Yfgn	23	9.9	9.9
Trazodone Hydrochloride	16	9.6	9.6
Posaconazole Delayed-Release	11	9.3	9.3
Tretinoin	8	9.2	9.2
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	8	9.1	9.1
Bendamustine Hcl	15	9.0	9.0
Paroxetine Hydrochloride Hemihydrate	32	9.0	9.0
Pertuzumab	26	9.0	9.0
Paroxetine	32	8.8	8.9
Levetiracetam	120	8.8	8.8
Alemtuzumab	18	8.7	8.7
Vemurafenib	11	8.5	8.5
Zinc	22	8.3	8.4
Valproic Acid	28	8.3	8.3
Zinc Chloride	22	8.3	8.3
Vincristine Sulfate	25	8.0	8.0
Zinc Gluconate	22	7.9	7.9
Midazolam	21	7.8	7.8
Everolimus Tablets	14	7.8	7.8
Meropenem	26	7.6	7.6
Midazolam Hydrochloride	21	7.3	7.3
Mycophenilic Acid	16	7.2	7.2
Enoxaparin Sodium	43	7.1	7.1
Clonidine	38	7.0	7.0
Anti-Thymocyte Globulin (Rabbit)	6	6.9	6.9
Cladribine	7	6.8	6.8
Trastuzumab	49	6.8	6.8
Diazepam Oral Solution (Concentrate)	63	6.7	6.7
Diazepam Oral	63	6.7	6.7
Extended Phenytoin Sodium	12	6.7	6.7
Doxorubicin Hydrochloride	23	6.6	6.6
Exemestane	15	6.5	6.5
Ifosfamide	15	6.5	6.5
Phenobarbital	10	6.4	6.4
Posaconazole	11	6.3	6.3
Ceftriaxone	22	6.3	6.3
Blinatumomab	7	6.2	6.2
Cyclophosphamide Injection, Solution	113	6.2	6.2
Cyclophosphamide	113	6.2	6.2
Cyclophosphamide For Injection	113	6.2	6.2
Norepinephrine	7	6.1	6.1
Doxorubicin	57	6.1	6.1
Lacosamide	24	6.0	6.0
Baclofen	54	5.9	5.9
Aripiprazole Oral	26	5.9	5.9
Aripiprazole Orally Disintegrating	26	5.9	5.9
Phenytoin	13	5.8	5.8
Trametinib	15	5.8	5.8
Dabrafenib	13	5.8	5.8
Ceftriaxone Sodium	22	5.4	5.4
Linezolid	17	5.3	5.3
Cefepime Hydrochloride	9	5.2	5.2
Bupivacaine	5	5.0	5.0
Pyrazinamide	5	4.9	5.0
Fam-Trastuzumab Deruxtecan-Nxki	5	4.6	4.6
Clobazam	12	4.6	4.6
Granisetron	5	4.4	4.4
Capecitabine	43	4.4	4.4
Cisplatin	36	4.3	4.3
Siponimod	4	4.2	4.2
Polatuzumab Vedotin	4	3.8	3.8
Crizotinib	5	3.7	3.7
Lapatinib	6	3.6	3.6
Eculizumab	20	3.4	3.4
Ozanimod Hydrochloride	3	3.4	3.4
Pegfilgrastim	32	3.0	3.0
Encorafenib	3	2.8	2.8
Ethyl Alcohol	8	2.7	2.7
Atezolizumab	11	2.6	2.6
Vigabatrin	3	1.9	1.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.